

8 September 2023

**Braveheart Investment Group plc**  
**("Braveheart" or the "Group")**

**Investment update - Kirkstall Limited**

Braveheart Investment Group (AIM: BRH), announces an update on Kirkstall Limited ("Kirkstall" or the "Company"), a company within the Group's investment portfolio.

Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy and Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford has developed an "organ on a chip" model of an innovative, milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer.

This is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated. The model uses the Kirkstall's Quasi Vivo® platform, a unique milli-fluidic system. This innovation will enable the observation of the *in vitro* performance of drugs designed for treating brain cancer and central nervous system diseases such as Alzheimer's.

Braveheart holds a 86.11% equity interest in Kirkstall. In addition, it has provided unsecured interest free loans to Kirkstall totalling £10,752 as at 31 March 2023.

**Trevor Brown, CEO of Braveheart Investment Group plc commented:** *"It is exciting to observe how collaboration between Kirkstall and Oxford University has resulted in an innovative and important application for the Quasi Vivo platform."*

For further information:

**Braveheart Investment Group plc**  
Trevor Brown CEO

Tel: 01738 587555

**Allenby Capital Limited (Nominated Adviser and Joint Broker)**  
James Reeve / George Payne

Tel: 020 3328 5656

**Peterhouse Capital Limited (Joint Broker)**  
Duncan Vasey / Lucy Williams

Tel: 020 7469 0936

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PFUGZGGLVNLGFZM